Clobazam + Placebo
Phase 3Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dravet Syndrome
Conditions
Dravet Syndrome
Trial Timeline
Mar 1, 2015 → Aug 1, 2015
NCT ID
NCT02174094About Clobazam + Placebo
Clobazam + Placebo is a phase 3 stage product being developed by Lundbeck for Dravet Syndrome. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02174094. Target conditions include Dravet Syndrome.
What happened to similar drugs?
2 of 11 similar drugs in Dravet Syndrome were approved
Approved (2) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02174094 | Phase 3 | Withdrawn |
Competing Products
15 competing products in Dravet Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 32 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 29 |
| fenfluramine | UCB | Approved | 50 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 26 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 40 |
| fenfluramine | UCB | Phase 3 | 44 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 40 |
| Clobazam | Lundbeck | Phase 3 | 29 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Approved | 47 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 41 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 26 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 33 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 41 |